FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center

Nüks/Refrakter Akut Lösemili Çocuklarda Idarubisin Eklenerek veya Eklenmeden FLAG Tedavisi: Bir Türk Pediatrik Hematoloji Merkezi Deneyimi

Şebnem Yılmaz Bengoa, Eda Ataseven, Deniz Kizmaçoğlu, Fatma Demir Yenigürbüz, Melek Erdem, Hale Ören

Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey

Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.

Materials and Methods: Between September 2007 and May 2015, 18 children with refractory/relapsed AL attending our center, treated with a FLAG regimen with or without IDA, were included. The primary end point was the remission status of the bone marrow sampled after the first/second course of chemotherapy. The second end point was the duration of survival after hematopoietic stem cell transplantation (HSCT).

Results: Complete remission (CR) was achieved in 7 patients (38.8%) after the first cycle, and at the end of the second cycle the total number of patients in CR was 8 (42.1%). All patients in CR underwent HSCT. The CR rate in patients who had IDA in combination therapy was 28.6%, and it was 50% in patients treated without IDA (p=0.36). Mean survival duration in transplanted patients was 24.7±20.8 months (minimum-maximum: 2–70, median: 25 months), and it was 2.7±1.64 months (minimum-maximum: 0–5, median: 3 months) in nontransplanted patients. Five of them (27.7%) were still alive at the end of the study and in CR. The median time of follow-up for these patients was 33 months (minimum-maximum: 25–70 months).

Conclusion: FLAG regimens with or without IDA produced a CR of >24 months in 27.7% of children with relapsed/refractory AL and can be recommended as therapeutic options prior to HSCT in developing countries.

Keywords: Relapsed/refractory leukemia, FLAG regimen, Chemotherapy, Childhood

Amaç: Nüks/refrakter akut lösemili (AL) çocuklarda daha yüksek sağkalım sağlamabilecek en uygun tedavi yaklaşımı halen bilinmemektedir. Gelişmekte olan ülkelerde bu hasta grubunda etkin olduğu iyi bilinen ve yakın zamanda geliştirilmiş bazı ilaçla ulaşılama güçlük yaşanmaktadır. Biz relaps/refrakter akut lenfoblastik lösemii ve akut miliyel lösemii çocuklarda idarubisin (IDA) eklenmiş veya eklenmemiş, fludarabin, yüksek doz sitarabin ve granülosit koloni stimüle edici faktör (FLAG tedavisi) kombinasyonunun etkinliğini değerlendirirdik.

Gereç ve Yöntemler: Çalışmaya Eylül 2007 ve Mayıs 2015 arasında merkezimizde izlenen, IDA eklenmiş veya eklenmemiş FLAG tedavisi verilen, 18 relaps/refrakter AL’li çocuk dahil edildi. Birincil sonlanım noktası kemoterapi sonrası alınan kemik iliği oranı ve ikinci sonlanım noktası ise hematopoetik kök hücre nakli (HKHN) sonrası sağkalım süresi olarak belirlendi.

Bulgular: Çocukların yedisinde (%38,8) ilk siklus, toplam olarak sekizinde (%62,1) ise ikinci siklus sonrasında tam remisyon (TR) elde edildi. TR’deki tüm hasta HKHN yapıldı. Kombinasyon tedavisine IDA eklenmiş olan hastalarda TR oranı %28,6, IDA eklenmemiş olanlarda %60 idi (p=0,36). HKHN yapılmış hastalarda ortalama sağkalım süresi 24,7±20,8 ay (minimum-maximum: 2–70, medyan: 25 ay), yapılmaması olanlarda 2,7±1,64 ay (minimum-maximum: 0–5, medyan: 3 ay) idi. Bu hastaların beşinde (%27,7) halen sağ ve TR’dedir. Yaşayan hastaların median izlem süresi 33 ay (minimum-maximum: 25–70 ay) idi.

Sonuç: IDA eklenmiş veya eklenmemiş FLAG tedavisi nüks/refrakter AL’li çocukların %27,7’sinde 24 aydan daha uzun süreli sağkalım sağlamıştır ve gelişmekte olan ülkelerde HKHN sonrası tedavi seçeneği olarak önerilebilir.

Anahtar Sözcükler: Nüks/refrakter lösemi, FLAG tedavisi, Kemoterapi, Çocuklık çağı
Introduction

Despite the improved prognosis in pediatric acute leukemias (ALs), survival rates are low for patients with relapsed or refractory disease [1,2]. Treatment approaches for these patients are not uniform. Effective reinduction regimens are needed and it has been shown that hematopoietic stem cell transplantation (HSCT) can offer long survival times [2,3]. In developing countries, it is difficult to obtain some of the more recent drugs for optimal therapy, and mostly well-known drugs proven to be effective are used. Regimens with the combination of fludarabine (FL), cytarabine, idarubicin (IDA), and granulocyte colony-stimulating factor (G-CSF) have been widely used for poor-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and relapsed or refractory acute lymphoblastic leukemia (ALL) in adults [4,5]. Pediatric series of AL cases with poor prognosis treated with these regimens are limited in the literature [6,7,8,9].

FL, a fluorinated purine analog, and high-dose cytarabine are effective in the treatment of ALs [10]. The combination of FL with cytarabine appears to have a synergistic effect. A positive correlation has been found between the intracellular level of the active metabolite of cytarabine, Ara-C 5’-triphosphate (Ara-CTP), and remission rates. FL triphosphate, the active metabolite of FL, inhibits ribonucleotide reductase and increases intracellular Ara-CTP. Administration of fludarabine prior to cytarabine may enhance the clinical efficacy of cytarabine [11]. IDA has also been added to the combination to increase the antileukemic effect [6,7,8,9]. G-CSF prior to FL may increase the efficacy of chemotherapy by increasing the fraction of leukemic cells in the S-phase [12].

The combination regimen of FL, high-dose cytarabine, and G-CSF (FLAG) with or without IDA has been used in relapsed/refractory acute AML and ALL patients since 2007 in our clinic. Our aim was to evaluate the rate of complete remission (CR) and duration of survival after HSCT with this regimen.

Materials and Methods

Patients

Between September 2007 and May 2015, 18 children (15 boys and 3 girls) with refractory relapsed AL attending our center were treated with a FLAG regimen with or without IDA. The median age at treatment was 12 years (minimum-maximum: 9 months to 17 years). Ten patients had a diagnosis of ALL (6 precursor B-cell and 4 T-cell ALL) and 8 had AML (2 AML-M2, 2 AML-M4, 1 AML-M5, 2 secondary AML, and 1 myeloid sarcoma). Of the 10 children with ALL, 3 cases were primary refractory, 3 first-relapsed, and 4 second-relapsed (all of them were refractory to the ALL relapse protocol), while of the 8 children with AML, 5 cases were first-relapsed and 3 primary refractory.

One patient with myeloid sarcoma received the FLAG regimen after his first relapse, underwent autologous HSCT, relapsed 20 months after transplantation, and received the second course of the FLAG regimen.

At the time of treatment 13 patients had isolated bone marrow infiltration, 3 had isolated extramedullary disease, and 3 had combined disease. The extramedullary disease site was the central nervous system in 4 patients, testis in 1 patient, and lymph node in 1 patient.

All parents signed written informed consent forms before the start of the regimens.

Treatment

Fludarabine at 30 mg/m²/day was administered intravenously over 30 min and cytarabine at 2 g/m²/day was administered intravenously over 3 h starting 3.5 h after completing the fludarabine infusion for 4 consecutive days (days 1-4). IDA was given at 12 mg/m²/day by a 1-h infusion for 3 consecutive days (days 2-4) starting 1 h before the cytarabine infusion [7]. G-CSF was given at 200 or 400 µg/m²/day from day 0 to the first day of absolute neutrophil count (ANC) of >1000/µL in 10 patients, while it was started 48 h after completion of treatment in 8 patients.

Nineteen courses and 30 cycles were administered to 18 patients. In 9 courses 1 cycle, in 9 courses 2 cycles, and in 1 course 3 cycles of treatment regimen were administered. Detailed information is given in Table 1.

IDA was not given to the previously heavily treated 12 patients to decrease the rate of cardiotoxicity. If CR could not be achieved after the first cycle, then IDA was added to the FLAG regimen.

All patients routinely received trimethoprim/sulfamethoxazole and antifungal prophylaxis. Patients with response to treatment underwent autologous HSCT if they had an eligible donor.

The toxicity of the regimen was assessed according to the Common Toxicity Criteria of the World Health Organization [13].

Assessment of Response

Bone marrow examination was performed when ANC was >1000/µL or at day 30 after chemotherapy. CR was defined as the absence of physical signs of leukemia, no extramedullary blasts, no blasts in peripheral blood, <5% blasts in bone marrow (BM) with evidence of normal hematopoiesis, and no blasts in the cerebrospinal fluid. Partial remission (PR) was defined as marrow blasts between 5% and 25%. Aplasia was defined as blasts <5% in BM or peripheral blood, no extramedullary blasts, no evidence of hematopoietic regeneration, and no regeneration in peripheral blood count [14].
| Patient No. | Age at FLAG course (years)/sex | Diagnosis | Duration of remission before relapse (first/second relapse) | Treatment regimen and response | Duration of remission after FLAG/FLAG-IDA | Duration of survival/outcome |
|------------|-------------------------------|-----------|--------------------------------------------------------|-------------------------------|-----------------------------------------|--------------------------------|
| 1          | 16/M                          | Precursor B-cell ALL/first relapse | 12 months | 1st FLAG-IDA: Aplasia                                   | _                              | 3 months/died with relapse |
| 2          | 7/M                           | Precursor B-cell ALL/first relapse | 17 months | 1st FLAG: No response                                   | _                              | 4 months/died with relapse |
| 3          | 12/F                          | Precursor B-cell ALL/refractory after first relapse | 10 months | 1stFLAG-IDA: Aplasia                                   | _                              | 3 months/died with relapse and infection |
| 4          | 14/M                          | T-cell ALL/refractory              | _          | 1st FLAG: Not evaluated, died at 15th day after chemotherapy | _                              | - /died with infection |
| 5          | 12/M                          | Precursor B-cell ALL/second relapse | 21 months/16 months | 1st FLAG: PR 2nd FLAG-IDA: Aplasia | _                              | 3 months/died with infection |
| 6          | 11.5/M                        | Precursor B-cell ALL/first relapse | 23 months | 1st FLAG: CR Aplasia 2nd FLAG-IDA: Aplasia | 10 months | 10 months/died with GVHD and infection |
| 7          | 15/M                          | T-cell ALL/refractory              | _          | 1st FLAG: CR Aplasia 2nd FLAG: CR Aplasia              | 25 months | 25 months/alive |
| 8          | 14/F                          | Precursor B-cell ALL/second relapse | 18 months/17 months | 1st FLAG: CR 2nd FLAG: CR Aplasia Aplasia | 2 months | 2 months/died with GVHD and infection |
| 9          | 16/M                          | T-cell ALL/refractory              | _          | 1st FLAG: CR Aplasia 2nd FLAG: CR Aplasia              | 33 months | 33 months/alive |
| 10         | 14/M                          | T-cell ALL/first relapse           | 9 months  | 1st FLAG: No response 2nd FLAG-IDA: CR Aplasia         | 5 months | 5 months/died with infection and multiorgan failure |
| 11         | 4.5/M                         | AML-M4/first relapse               | 10 months | 1st FLAG: CR 2nd FLAG: CR Aplasia Aplasia              | 33 months | 33 months/alive |
| 12         | 15/M                          | AML-M2/first relapse               | 10 months | 1st FLAG-IDA: Not evaluated, died at 17th day after chemotherapy | _                              | - /died with infection |
| 13         | 9/F                           | AML-M4                            | 2.5 months | 1st FLAG: No response 2nd FLAG: No response            | _                              | 4 months/died with refractory leukemia and infection |
| 14         | 8.5/M                         | AML secondary to MDS/refractory    | _          | 1st FLAG-IDA: No response 2nd FLAG: No response        | _                              | 3 months/died with refractory leukemia and infection |
| 15         | 0.8/M                         | AML-MS/first relapse               | 10.5 months | 1st FLAG: No response 2nd FLAG: No response            | _                              | 2 months/died with relapse |
| 16         | 5/M                           | AML secondary to MDS/refractory    | _          | 1st FLAG: Aplasia Aplasia                              | _                              | 25 months/alive |
| 17         | 15/M                          | AML-M2/first relapse               | 9 months  | 1st FLAG-IDA: CR 2nd FLAG: CR Aplasia                  | 70 months | 70 months/alive |
| 18, first course | 11.5/M                  | Myelosarcoma/first relapse         | 36 months | 1st FLAG: CR 2nd FLAG: CR Aplasia                      | 24 months | After 20 months of posttransplant remission, he relapsed with AML |
| 18, second course | 14/M                    | AML                               | 20 months | 1st FLAG: CR 2nd FLAG: CR 3rd FLAG: Relapsed           | _                              | 5 months/died with relapse and infection |

M: Male, F: female, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, CR: complete remission, Allo-HSCT: allogeneic hematopoietic stem cell transplantation, IDA: idarubicin
The primary end point was status of the bone marrow sampled after the first/second course of chemotherapy. The second end point was the duration of survival after HSCT.

Duration of survival was calculated from the start of the treatment regimen up to the last follow-up or mortality.

**Statistical Analysis**

SPSS 15.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Analytical characteristics were given as percentage, mean and SD, or median. Data were analyzed for statistically significant differences using the Mann-Whitney U test and the chi-square test. Group differences with p<0.05 were considered to be statistically significant. Duration of survival and time of follow-up were calculated with descriptive statistics. With a total of only 18 cases the use of further statistical methods was limited.

**Results**

**Treatment Response**

Thirty cycles were administered in 18 patients. Age, sex, diagnosis, remission duration before relapses, treatment regimen and response, remission duration after treatment regimen, and duration of survival/outcome of patients are shown in Table 1. After the first cycle, CR was achieved in 7 (38.8%) patients, PR was achieved in 1 (5.3%), remission was not observed in 5 (26.3%), and aplasia was found in 3 (15.7%). Two patients could not be evaluated for response because of early death after the first FLAG treatment. After the second cycle, one nonresponder achieved CR. CR rate in patients who did not receive G-CSF starting with the chemotherapy was 50% and CR rate in patients who received G-CSF with the beginning of chemotherapy was 36.4%; the difference was not significant (p=0.563). CR rate in patients who had IDA in the combination therapy was 28.6% and CR rate was 50% in patients treated without IDA (p=0.360). There was no difference in CR rate according to the duration of remission before the treatment (p=0.770).

**Toxicity**

All children had severe myelosuppression and were intensively supported with blood products. The median time of neutrophil recovery (>500/µL) was 24 days (minimum-maximum: 15-45), and that of platelet recovery (>20,000/µL) was 20 days (minimum-maximum: 15-73). Febrile neutropenia (FN) occurred after 26 (86.6%) cycles of regimens. FN was observed after 6 (85.7%) cycles with additional IDA and after 20 (87%) cycles without IDA. There was no difference in FN rate according to additional IDA (p=0.677). Most patients developed grade 3-4 mucositis. Seven children had transient mild hepatotoxicity (36.8%). There was no serious cardiotoxicity. Two patients (11.1%) had documented infections (blood cultures showed *Escherichia coli* and a yeast-like organism in 1 patient, and *Klebsiella pneumoniae* in 1 patient). Two patients, a primary refractory T-cell ALL patient and a relapsed AML patient with documented infection, died before the time of remission evaluation. Two patients (11.1%) had pulmonary invasive fungal infection.

**Duration of Survival**

All patients in CR and one patient with AML secondary to MDS who had aplasia after the regimen, in total 9 (50%) patients, underwent subsequent allogeneic HSCT. Four patients were transplanted from matched sibling donors, 2 from matched unrelated donors, and 3 from haploidentical donors. Four patients died after HSCT; in 3 patients, the cause of death was infection. The fourth patient (case 18) relapsed after HSCT and had a second course with 3 cycles of FLAG; he was in remission after the first 2 cycles but relapsed after the third cycle and died.

Mean duration of survival in transplanted patients was 24.7±20.8 months (minimum-maximum: 2-70, median: 25 months) and it was 2.7±1.64 months (minimum-maximum: 0-5, median: 3 months) in the nontransplanted patients.

As a result, 5 (27.7%) patients who underwent HSCT are still alive and in CR. Two patients underwent allogeneic HSCT from their siblings, 2 underwent allogeneic HSCT from unrelated matched donors, and 1 underwent haploidentical HSCT from his mother. The median time of follow-up for these patients was 33 months (minimum-maximum: 25-70 months). Three were AML (one case secondary to MDS) and 2 were ALL patients.

**Discussion**

The treatment of children with relapsed or refractory AL is still challenging. Regimens containing FL and high-dose cytarabine with or without IDA have been used in this patient group, and the first results were published in 1996 [6]. In our study, the CR rate after 2 cycles was 42.1% (most of these patients were in CR after the first cycle), all of these patients could proceed to HSCT, and 27.7% survived. Fleischhack et al. reported a CR rate of 73.9% in patients with poor-prognosis AML; 47.8% underwent HSCT and 39.1% remained in CR [7]. In the study conducted by McCarthy et al., in a group of ALL, AML, and biphenotypic AL patients using the FLAG regimen the CR rate was 70%; 68.4% of the patients underwent HSCT and 36.8% were alive at the end of the study [15]. Tavil et al. from Turkey presented the results of 25 relapsed/refractory AL patients. The CR rate was 60%, 49% of their patients could proceed to HSCT, and 20% survived [8]. Yalman et al., also from Turkey, reported a CR rate of only 17.6% in 17 poor-prognosis AL patients; 2 underwent HSCT and only 1 child with a previous HSCT survived after donor lymphocyte infusion [9].
The CR rate in our patients who had IDA in combination therapy was 28.6% and it was 50% in patients treated without IDA; the difference was not statistically significant. Patients who received IDA-FLAG were mostly those who had refractory disease. This might be the reason for the lower response rate.

All of our patients experienced severe myelosuppression, FN developed after 86.6% of the cycles, and 2 patients (11.1%) died early with infection, shortly after chemotherapy (15th and 17th days). The addition of IDA to the FLAG regimen did not change the risk of FN. Invasive fungal infection was observed in a total of 3 patients (16.6%). The reported toxicity of these regimens is similar to rates reported in the literature [8,15].

In some recent studies, it was demonstrated that with the addition of agents like liposomal forms of daunorubicin and doxorubicin instead of IDA to treatment regimens containing FL and high-dose cytarabine, CR can be achieved in higher rates with less systemic toxicity in children with refractory/refractory AL [16,17]. In developing countries such as Turkey, liposomal forms of these anthracyclines are not available and cannot be used due to economic reasons.

Because of the increased use of unrelated and haploidentical donors nowadays, even when a suitable family donor is lacking, the chance of transplantation with alternative stem cell sources in a short time after CR is better. Therefore, achieving CR in poor-prognosis AL with effective treatment regimens may result in better outcomes. Five of our patients achieved a CR of >24 months after HSCT.

The role of G-CSF in the management of relapsed/refractory AL has been tested widely and remains controversial [18]. Most of the trials demonstrated a modest reduction in the duration, but not the depth, of neutropenia [16,18,19]. The effects of G-CSF on duration of survival, incidence of severe infection, and duration of hospitalization are variable, but in developing countries, the death rates due to FN are higher than in developed countries, and G-CSF given with chemotherapy or after chemotherapy is still common. Even though a trend towards an increased incidence of relapses with G-CSF treatment in children with AML that overexpress the differentiation-defective G-CSFR isoform IV has been reported, the number of these cases is very low and G-CSF continues to be a part of the FLAG regimen [16,20]. We used G-CSF in all of our patients since the FN risk is high in our clinic. We did not find any statistically significant difference in CR rate whether we started G-CSF at day 0 or after completion of chemotherapy.

**Conclusion**

In conclusion, FLAG regimens with or without IDA produced a CR of >24 months in 27.7% of children with refractory/refractory AL and can be recommended as a therapeutic option prior to HSCT with appropriate supportive measurements in developing countries.

**Ethics**

Ethics Committee Approval: The study was a retrospective analysis, and we used data from hospital records; Informed Consent: All parents signed written informed consent forms before the start of the regimens.

**Authorship Contributions**

Concept: Şebnem Yılmaz Bengoa, Hale Ören; Design: Şebnem Yılmaz Bengoa; Data Collection or Processing: Şebnem Yılmaz Bengoa, Eda Ataseven, Deniz Kızımaçoğlu, Fatma Demir Yenigürbüz, Melek Erdem; Analysis or Interpretation: Şebnem Yılmaz Bengoa, Hale Ören; Literature Search: Şebnem Yılmaz Bengoa; Writing: Şebnem Yılmaz Bengoa, Hale Ören.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

**References**

1. Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U. Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study. Klin Padiatr 1992;204:253-257.
2. Einsiedel HG, von Stackelberg A, Hartmann R, Fenger R, Schrapp M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 2005;23:7942-7950. Erratum in: J Clin Oncol 2008;26:2233.
3. Sander A, Zimmermann M, Dziczak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ, Creutzig U. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010;24:1422-1428.
4. Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, Prentice HG. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004;124:26-32.
5. Yavuz S, Paydas S, Disol U, Sahin B. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 2006;13:389-393.
6. Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U. IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)—an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study. Klin Padiatr 1996;208:229-235.
7. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998;102:647-655.
8. Tavil B, Aytac S, Balci YL, Unal S, Kuskonmaz B, Yetgin S, Gurgey A, Tuncer M, Gumruk F, Uckan D, Cetin M. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children...
with poor-prognosis acute leukemia: the Hacettepe experience. Pediatri Hematol Oncol 2010;27:517-528.

9. Yalman N, Sarper N, Devecioglu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Agaoglu L, Gedikoglu G. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 2000;42:198-204.

10. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, Estey E, Plunkett W. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 1994;14:11-16.

11. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-124.

12. Tosi P, Visani G, Ottaviani E, Manfori S, Zinzani PL, Tura S. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994;8:2076-2082.

13. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

14. Redner A. Leukemias. In: Lanzkowsky P, (ed). Manual of Pediatric Hematology and Oncology, 5th ed. New York, Academic Press, 2011.

15. McCarthy AJ, Pitcher LA, Hann IM, Oakhill A. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatri Oncol 1999;32:411-415.

16. Kapers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, Armendariz H, Dworzak M, Ha SY, Hasle H, Hovi L, Maschan A, Bertrand Y, Leverand GG, Razzouk BI, Rizzari C, Smisek P, Smith O, Stark B, Creutzig U. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013;31:599-607.

17. Quarello P, Berger M, Rivetti E, Galletto C, Masetti R, Manicone R, Barisone E, Pession A, Fagioli F. FLAG–liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients. J Pediatri Hematol Oncol 2012;34:208-216.

18. Miligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK; NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006;107:4614-4622.

19. Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiechi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F; Gran AML Study Group. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002;116:103-112.

20. Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrmeister T, Roetgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isofrom IV is associated with a higher incidence of relapse. J Clin Oncol 2010;28:2591-2597.